4698-96-8

Basic information

• Product Name: 2-((1,1’-biphenyl-4-yloxy)methyl)-oxiran
• Synonyms: 2-((1,1’-biphenyl-4-yloxy)methyl)-oxiran;4-biphenylylglycidylether;ether,4-biphenylyl2,3-epoxypropyl;p-phenylphenylglycidylether;1-(biphenyl-4-yloxy)-2,3-epoxypropane;Biphenyl-4-ylglycidyl ether;Glycidyl(4-biphenylyl) ether;Ccris 2066
• CAS NO: 4698-96-8
• Molecular Formula: C₁₅H₁₄O₂
• Molecular Weight: 226.27046
• EINECS: 225-174-7
• Mol File: 4698-96-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 374.2°Cat760mmHg
• Flash Point: 157.6°C
• Appearance: /
• Density: 1.136g/cm³
• Vapor Pressure: 1.83E-05mmHg at 25°C
• Refractive Index: 1.581
• CAS DataBase Reference: 2-((1,1’-biphenyl-4-yloxy)methyl)-oxiran(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((1,1’-biphenyl-4-yloxy)methyl)-oxiran(4698-96-8)
• EPA Substance Registry System: 2-((1,1’-biphenyl-4-yloxy)methyl)-oxiran(4698-96-8)

Safety Data

• Hazardous Substances Data: 4698-96-8(Hazardous Substances Data)

Usage

General Description

2-((1,1’-biphenyl-4-yloxy)methyl)-oxiran is a chemical compound with the molecular formula C20H18O2. It is also known by its IUPAC name, 2-((4-biphenylyloxy)methyl)oxirane. 2-((1,1’-biphenyl-4-yloxy)methyl)-oxiran is an epoxide, which means it contains a three-membered ring consisting of one oxygen atom and two carbon atoms. It is commonly used as a building block in organic synthesis and in the production of various chemical products. Its reactive nature makes it useful in the formation of polymers, resins, and other materials. Additionally, its unique structure and properties make it a potential candidate for pharmaceutical and agrochemical applications.

InChI:InChI=1/C15H14O2/c1-2-4-12(5-3-1)13-6-8-14(9-7-13)16-10-15-11-17-15/h1-9,15H,10-11H2/t15-/m0/s1

Upstream product

• 92-69-3 4-Phenylphenol 
• 115314-14-2 (2s)-(+)-glycidyl 3-nitrobenzenesulfonate 
• 3132-64-7 1,2-Epoxy-3-bromopropane 
• 106-89-8 epichlorohydrin 

Downstream Products

• 5741-13-9 1-([1,1'-biphenyl]-4-yloxy)-3-(isopropylamino)propan-2-ol 
• 5305-17-9 C₁₉H₂₃NO₂ 
• 5262-74-8 1-biphenyl-4-yloxy-3-morpholin-4-yl-propan-2-ol 
• 61485-61-8 VUF14176 
• 1399845-85-2 C₂₃H₂₄FNO₂ 
• 5305-36-2 1-(Biphenyl-4-yloxy)-3-diethylamino-propan-2-ol 
• 1399845-88-5 C₂₂H₂₂FNO₂ 
• 1399845-86-3 C₂₂H₂₁F₂NO₂ 
• 1399845-84-1 C₂₂H₂₃NO₂ 
• 127038-44-2 4-(3-(biphenyl-4-yloxy)-2-hydroxypropylthio)phenol 
• 797814-46-1 3-(3'-(4''-phenylphenoxy)-2'-hydroxypropyl)-5,5-dimethylimidazolidine-2,4-dione 
• 81015-20-5 1-[N-benzyl-2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-(4-biphenyloxy)-2-propanol 
• 391901-99-8 (2 S)-1-[(4-aminophenethyl)amino]-3-([1,1'-biphenyl]-4-yloxy)-2-propanol 

Relevant articles and documents

Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents

Malignant melanoma (MM) presents as the highest morbidity and mortality type in skin cancer. Herein, inspired by the previously reported anti-melanoma effect of propranolol, a widely applied β adrenergic receptor antagonist as cardiovascular drug, we set out to exploit its potential as anti-melanoma therapy based on the drug repurposing strategy. Structural optimization of propranolol yielded 5m, which exhibits dramatically improved potency on human melanoma cell growth (1.98–3.70 μM), compared to propranolol (59.5–75.8 μM). Further investigation demonstrated that 5m could inhibit colony formation of melanoma cell line (completely abolished at 2 μM for 5m, partially inhibited at 50 μM for propranolol), induce cell apoptosis and cell cycle arrest in the G2/M phase (both observed at 1 μM). Preliminary mechanism study indicated that 5m could disrupt the cellular microtubule network, which suggested tubulin as a potential target. Docking study provided a structural insight into the interaction between 5m and tubulin. In summary, our study presents a drug repurposing case that redirects a cardiovascular agent to an anti-melanoma agent.

A biphenyl type process for the preparation of a glycidyl ether (by machine translation)

The purpose of this invention is to offer a kind of through the epoxy bromo propane and couplet phenol compound under phase transfer catalyst in the reactive diluent is obtained by reacting biphenyl glycidyl ether synthesis method. Characterized in that according to the following steps : (1) the biphenol compounds and sodium carbonate according to the molar ratio of the 1 [...] 1.2 by adding to the reaction vessel, in 65-70 °C stirring under 10 hours, a supernatant liquid 2nd-step reaction. (2) a certain amount of obtained product and catalyst is added to the reaction flask, propane takes the epoxy bromine -by-drip through the constant pressure dropping funnel to the reaction flask with stirring, in 70-80 °C stirring under 4-7 hours, separating and purifying, that is, to obtain the product. The product obtained by this invention the epoxy reactive diluent, a chlorine-containing compound stabilizer, such as fabric finishing agent has wide application. Furthermore, it is also for synthesizing many industrial products: such as antistatic agent, emulsifier, plastic additives, cosmetics, an important intermediate of surface active agents and the like. (by machine translation)

Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity

Lysine demethylases play an important role in epigenetic regulation and thus in the development of diseases like cancer or neurodegenerative disorders. As the lysine specific demethylase 1 (LSD1/KDM1) has been strongly connected to androgen and estrogen dependent gene expression, it serves as a promising target for the therapy of hormone dependent cancer. Here, we report on the discovery of new small molecule inhibitors of LSD1 containing a propargylamine warhead, starting out from lysine containing substrate analogues. On the basis of these substrate mimicking inhibitors, we were able to increase potency by a combination of similarity-based virtual screening and subsequent synthetic optimization resulting in more druglike LSD1 inhibitors that led to histone hypermethylation in breast cancer cells.